SEC Tracker
Get the app

CymaBay Therapeutics

Dorling Janet (Director) plans to sell 6,000 shares, about $120,422

Form
144
Filed
Importance
Routine
Document
Form 144
  1. Approximate sale date: Dec 11, 2023
  2. Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
  3. Shares acquired by: Stock Option Exercise
  4. 10b5-1 plan adopted: Aug 9, 2023

All of Dorling Janet's insider filings, holdings and planned sales

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when CymaBay Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX

Data on this page was fetched . The filing on SEC.gov is the record.